New heart pump aims to make risky angioplasty safer

NCT ID NCT07675005

Not yet recruiting Disease control Sponsor: Life Shield Medical Technology Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial compares a new temporary heart pump called VentriCure with standard ECMO support in people with coronary artery disease undergoing high-risk angioplasty. The study includes 220 patients whose hearts are weak or who have severe heart failure. The goal is to see if VentriCure reduces major complications like death, heart attack, stroke, or major bleeding within 30 days after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VentriCure left ventricular assist system (a temporary heart pump)
What this could lead to: If successful, VentriCure could offer a safer, more effective way to support the heart during high-risk angioplasty, reducing complications compared to ECMO.
What could go wrong: This is an early-stage device trial with 220 participants. The device may not prove safer or more effective than ECMO, and risks include bleeding, stroke, or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.